Ekso Bionics® to Showcase the Latest Features of the EksoGT™ Wearable Exoskeleton at 2017 AAPM&R Annual Assembly
10 October 2017 - 11:00PM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that the company will showcase the latest features of the
EksoGT™ wearable exoskeleton at the 2017 American Academy of
Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
taking place October 12-15, 2017, in Denver, CO. For the first time
at AAPM&R, attendees can learn how SmartAssist™ and EksoPulse™
technology can help them provide advanced personalized patient
care.
Live demonstrations of the EksoGT™, the first
and only exoskeleton cleared by the FDA for stroke and spinal cord
rehabilitation, will take place at booth #200. Clinicians will be
able to explore the technology firsthand, learn about the clinical
benefits, and engage with Company experts on exoskeleton
rehabilitation. The booth will also display a new video series
highlighting the experiences of patients and clinicians.
On Friday, October 13, Ekso Bionics will also be
hosting a Meet and Greet from 2:00 – 5:00 p.m. MT at their booth,
where attendees can connect with experts who are experienced with
using the EksoGT™ for stroke and spinal cord injury
rehabilitation.
The EksoGT™ enables individuals to stand up and
walk with a full weight bearing, reciprocal gait. The device
amplifies patient’s natural abilities and is designed to help them
get back on their feet earlier by aiding their re-learning of
correct step patterns and weight shifting.
The SmartAssist™ technology is the next
generation gait therapy software, allows physical therapy to vary
the support of the device for each leg independently – from full
power to free walking – and thereby offers personalized therapy
specific to the needs of a larger range of patients. EksoPulse™ is
an advanced cloud-based technology for physical therapists to
obtain insights in rehabilitation to capture patient progress and
allows further personalization of care in real-time.
AAPM&R is the foremost medical society for
the specialty of physical medicine and rehabilitation. More than
3,000 physiatrists from around the world are expected to attend the
Annual Assembly for educational sessions, networking events, and
research aimed at the diverse clinical and practice interest of
today’s physiatrists.
For more information on the AAPM&R Annual
Assembly and the academy, visit www.aapmr.org.
About Ekso Bionics®Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical, industrial and defense
applications. Founded in 2005, the company continues to build upon
its unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information,
visit: www.eksobionics.com.
About EksoGT™EksoGT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of a
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently, and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 80 million steps in over 185
rehabilitation institutions around the world.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie
Yamond917-371-2320cyamond@lazarpartners.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024